Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape
NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's.
"Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward."
Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital.
For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has:
Invested more than $370 million into over 765 drug discovery programs across 21 countries
Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research
Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval
Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention
Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer
Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether
Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission.
"Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable," said Mark Roithmayr, Chief Executive Officer of the ADDF. "He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day."
Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity.
The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease.
About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/statement-from-the-alzheimers-drug-discovery-foundation-on-the-passing-of-addf-co-founder-and-co-chairman-leonard-a-lauder-302481866.html
SOURCE Alzheimer's Drug Discovery Foundation
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
If You Invested $10K In Equity LifeStyle Stock 10 Years Ago, How Much Would You Have Now?
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Equity LifeStyle Properties Inc. (NYSE:ELS) is a real estate investment trust owning and operating manufactured home communities, RV resorts and campgrounds in North America. The company's stock traded at approximately $27.63 per share 10 years ago. If you had invested $10,000, you could have bought roughly 362 shares. Currently, shares trade at $63.07, meaning your investment's value could have grown to $22,827 from stock price appreciation alone. However, Equity LifeStyle also paid dividends during these 10 years. Don't Miss: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can Equity LifeStyle's dividend yield is currently 3.29%. Over the last 10 years, it has paid about $13.08 in dividends per share, which means you could have made $4,734 from dividends alone. Summing up $22,827 and $4,734, we end up with the final value of your investment, which is $27,561. This is how much you could have made if you had invested $10,000 in Equity LifeStyle stock 10 years ago. This means a total return of 175.61%. However, this figure is significantly less than the S&P 500 total return for the same period, which was 238.79%. Equity LifeStyle has a consensus rating of "Outperform" and a price target of $73.23 based on the ratings of 13 analysts. The price target implies a more than 16% potential upside from the current stock price. Trending: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. The company on April 21 announced its Q1 2025 earnings, posting FFO of $0.83, in line with expectations, while revenues of $387.33 million missed the consensus estimate of $398.72 million, as reported by Benzinga. For full-year 2025, the company expects net income per common share in the range of $1.97 to $2.07, and FFO per share of $3.01 to $3.11. Check out this article by Benzinga for five analysts' insights on Equity LifeStyle Properties. Given the expected upside potential, growth-focused investors may find Equity LifeStyle stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 3.29%. Read Next: Maximize saving for your retirement and cut down on taxes: . , which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Image: Shutterstock This article If You Invested $10K In Equity LifeStyle Stock 10 Years Ago, How Much Would You Have Now? originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Here's what to know about the twice-yearly preventative HIV shot
The Food and Drug Administration has approved a twice-yearly preventive HIV shot that could protect millions from the virus. People at risk for HIV may choose to take PrEP, a medication that helps prevent HIV infection. PrEp has been prescribed as a daily pill or a shot given every two months. This new twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP. Ian Haddock, a Houston man who participated in a study of the drug, told The Associated Press it 'expands the opportunity for prevention.' 'Now I forget that I'm on PrEP because I don't have to carry around a pill bottle,' he said. The shot, made by Gilead Sciences, is injected under the skin of the abdomen. It leaves a small 'depot' of medication that slowly absorbs into the body. 'This really has the possibility of ending HIV transmission,' Greg Millett, public policy director at amfAR, The Foundation for AIDS Research, told the AP. But the upheaval in U.S. healthcare — including cuts to public health agencies and Medicaid — and slashing of American foreign aid to fight HIV are clouding the prospects. Millett said "gaping holes in the system" in the U.S. and globally "are going to make it difficult for us to make sure we not only get lenacapavir into people's bodies but make sure they come back' even as little as twice a year. Gilead's drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. Gilead didn't immediately announce its price. The drug only prevents HIV transmission – it doesn't block other sexually transmitted diseases. Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide. Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere. About half of new infections are in women, who often need protection they can use without a partner's knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners. A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV. Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities, had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up. 'Men, women, gay, straight – it really just kinds of expands the opportunity for prevention,' he added. Just remembering a clinic visit every six months 'is a powerful tool versus constantly having to talk about, like, condoms, constantly making sure you're taking your pill every day.' 'Everyone in every country who's at risk of HIV needs access to PrEP,' Dr. Gordon Crofoot of Houston, who helped lead the study in men, told the AP. 'We need to get easier access to PrEP that's highly effective like this is.'
Yahoo
34 minutes ago
- Yahoo
Dow futures drop 150 points while oil prices jump after the U.S. bombs Iran's nuclear sites and widens Mideast conflict
Stock futures were down on Sunday as investors reacted to the U.S. attack on Iranian nuclear facilities on Saturday. Oil prices jumped amid fears that Tehran's retaliation could disrupt crude flows. The dollar tumbled as it continues to lose favor as a safe-haven asset, while gold climbed amid its continued surge as an alternative. U.S. stock futures signaled anxiety Sunday night as Wall Street weighed the implications of deepening U.S. involvement in the Middle East with its attack on Iran's nuclear facilities. Trump administration officials stressed that the airstrikes on Saturday night were targeted at Tehran's nuclear program and not aimed at regime change nor the start of a wider war that would require boots on the ground. But the direct involvement in offensive operations—which included massive 'bunker busters' dropped from stealth bombers—in what had been a conflict primarily between Israel and Iran still marked a major escalation. Futures for the Dow Jones Industrial Average fell 153 points, or 0.36%. S&P 500 futures were down 0.39%, and Nasdaq futures slipped 0.52%. Earlier on Sunday before premarket trading began, Wedbush Securities Managing Director Dan Ives had a bullish take for Wall Street in the wake of the U.S. attack on Iran. 'The market will view this Iran threat as now gone and that is a positive for growth in the broader Middle East and ultimately the tech sector,' he posted on X. 'It will take some time for this conflict to settle, but the market will view the worst is now in the rear-view mirror. Expect stocks up.' U.S. oil prices were up 2.8% at $75.84 per barrel after paring gains, and Brent crude leapt 2.7% to $79.07. While global markets had been expecting to see an initial jolt for oil, energy analytics firm Kpler pointed to other mitigating factors that could soften the blow eventually. 'Expect oil to open with a sharp 7–10% gap up as risk premiums surge. But don't be fooled, this may not last,' it posted on X. Iran's ability to retaliate is constrained, Kpler noted, saying a shutdown of the Strait of Hormuz is unlikely. Meanwhile, an early OPEC+ output boost for August of 411,000 barrels per day or more is increasingly likely, it added. Escalation of the Middle East conflict could be a test of whether U.S. bonds and the dollar are still seen as safe-haven assets in times of crisis. The yield on the 10-year Treasury edged up 1.4 basis points to at 4.389%. The dollar fell 0.32% against the euro and 0.25% against the yen. Gold, which is emerging as an alternative to the dollar, gave up gains to trade flat at $3,385.00 per ounce. The coming week will feature several key events and economic reports. Several Federal Reserve officials will speak throughout the week, including Chairman Jerome Powell who is appearing on Capitol Hill on Tuesday and Wednesday. Data for existing home sales, new home sales, and pending sales are due Monday, Wednesday, and Thursday, respectively, as the housing market shows signs of oversupply and weak demand. Also on Thursday, an initial reading on the trade deficit will come out amid Trump's tariffs along with durable-goods orders. On Friday, the Fed's preferred inflation gauge, the personal consumption and expenditures price index, is due. This story was originally featured on Sign in to access your portfolio
